Amgen’s biosimilar adalimumab (ABP 501), a biosimilar of AbbVie’s Humira, has received a positive opinion regarding marketing from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).
The active ingredient of ABP 501 is an anti-tumor necrosis factor (TNF)-alpha monoclonal antibody that has the same amino acid sequence as adalimumab. The decision is the first time an adalimumab biosimilar has been recommended for approval in the European Union (EU). ABP 501, branded as Amjevita (adalimumab-atto) in the United States, was approved by the FDA in September 2016. However, Amjevita has not yet been marketed in the US because AbbVie sued Amgen for patent infringement and the litigation is still in process.
ABP 501 was recommended for approval for the treatment of certain inflammatory diseases in adults, including moderate-to-severe rheumatoid arthritis (RA), psoriatic arthritis, severe ankylosing spondylitis (AS), severe axial spondyloarthritis without radiographic evidence of AS, moderate-to-severe plaque psoriasis, moderate-to-severe hidradenitis suppurativa, noninfectious intermediate, posterior and panuveitis, moderate-to-severe Crohn’s disease, and moderate-to-severe ulcerative colitis. The CHMP also recommended approval for the treatment of certain pediatric inflammatory diseases, including moderate-to-severe Crohn’s disease (ages 6 and older), severe chronic plaque psoriasis (ages 4 and older), enthesitis-related arthritis (ages 6 and older) and polyarticular juvenile idiopathic arthritis (ages 2 and older).
The CHMP’s positive opinion will be reviewed by the European Commission, which is authorized to approve medicines for the EU. The process typically takes approximately 60 days. If approved, ABP 501 will receive a centralized marketing authorization that is valid for the 28 countries in the EU. Norway, Iceland, and Liechtenstein, members of the European Economic Area, will make corresponding decisions on the basis of the EC’s decision.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Annual STADA Report Shows Record Profit Growth for 2023
March 25th 2024Germany-based biosimilar manufacturer STADA Arzneimittel reports strong financial performance in 2023 with double digit sales growth and billions in profits. The CEO credits the company’s success on their strong company culture and focus for innovation.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.